What is it about?
Glucocorticoids have potent antiinflammatory effects but their adverse metabolic effects limit their usefulness. Glucocorticoid-Induced Leucine Zipper (GILZ) protein has emerged as mediating the beneficial antiinflammatory effects of glucocorticoids. Acute kidney injury is accompanied by mobilization of immune/inflammatory mechanisms thereby contributing importantly to tissue injury. Thus, we examined the impact of GILZ treatment on the outcome of acute kidney injury.
Featured Image
Why is it important?
Acute kidney injury remains a significant clinical problem for which effective therapeutic options remain to be identified. Our results show that GILZ treatment promotes development of regulatory/suppressive phenotypes of neutrophils and T lymphocytes associated with reduction in kidney cell death and better functional outcome. Thus, therapeutic GILZ delivery offers the potential for preserving kidney function in clinical situations associated with acute renal injury; these include renal transplantation, partial nephrectomy, cardiac surgery, shock and repair of some forms of abdominal aneurysms.
Perspectives
The advent of cell-permeable GILZ fusion protein (which was used in our study) offers the unique opportunity to explore the impact of therapeutic GILZ delivery in conditions associated with dysregulation of immune and inflammatory mechanisms thereby avoiding adverse metabolic effects that are associated with the use of glucocorticoids.
Mahmood Mozaffari
Augusta University
Read the Original
This page is a summary of: Glucocorticoid-Induced Leucine Zipper Promotes Neutrophil and T-Cell Polarization with Protective Effects in Acute Kidney Injury, Journal of Pharmacology and Experimental Therapeutics, October 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET),
DOI: 10.1124/jpet.118.251371.
You can read the full text:
Contributors
The following have contributed to this page
